{
    "id": "9d52f9d2-f66b-4457-8cb7-c48a6e7d076f",
    "indications": {
        "text": "daysee\u2122 indicated females reproductive potential prevent pregnancy .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take one tablet daily mouth time every day 91 days order directed blister pack . ( 2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied daysee [ levonorgestrel ethinyl estradiol tablets usp ( 0.15 mg/0.03 mg ) ethinyl estradiol tablets usp ( 0.01 mg ) ] available extended-cycle wallets containing 13-week supply tablets : 84 light blue tablets , containing 0.15 mg levonorgestrel 0.03 mg ethinyl estradiol , 7 mustard tablets , containing 0.01 mg ethinyl estradiol . light blue tablets round , biconvex , film-coated tablets , debossed `` lu `` one side `` v21 `` side . mustard tablets round , biconvex , film-coated tablets debossed `` lu `` one side `` v22 `` side . supplied follows : daysee [ levonorgestrel ethinyl estradiol tablets usp ( 0.15 mg/0.03 mg ) ethinyl estradiol tablets usp ( 0.01 mg ) ] available extended cycle wallet 91 tablets packed pouch ( ndc 68180-846-11 ) . two pouches packed carton ( ndc 68180-846-13 ) . storage handling store 20\u00b0 c 25\u00b0 c ( 68\u00b0 f 77\u00b0 f ) ; excursions permitted 15\u00b0c 30\u00b0 c ( 59\u00b0f 86\u00b0 f ) [ usp controlled room temperature ] .",
    "adverseReactions": "daysee contraindicated females known develop following conditions : high risk arterial venous thrombotic diseases . examples include females known : smoke , age 35 [ boxed ( 5.1 ) ] . current history deep vein thrombosis pulmonary embolism [ ( 5.1 ) ] . cerebrovascular disease [ ( 5.1 ) ] coronary artery disease [ ( 5.1 ) ] . thrombogenic valvular thrombogenic rhythm diseases heart ( example , subacute bacterial endocarditis valvular disease , atrial fibrillation ) [ ( 5.1 ) ] . inherited acquired hypercoagulopathies [ ( 5.1 ) ] . uncontrolled hypertension hypertension vascular disease [ ( 5.3 ) ] . diabetes mellitus age 35 , diabetes mellitus hypertension vascular disease end-organ damage , diabetes mellitus > 20 years duration [ ( 5.7 ) ] . headaches focal neurological symptoms , migraine headaches aura , age 35 migraine headaches [ ( 5.8 ) ] . current diagnosis , history , breast cancer , may hormone sensitive [ ( 5.11 ) ] . liver tumors , acute viral hepatitis , severe ( decompensated ) cirrhosis [ ( 5.2 ) ( 8.6 ) ] . undiagnosed abnormal uterine bleeding [ ( 5.9 ) ] hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir , due potential alt elevations [ ( 5.4 ) ] .",
    "ingredients": [],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "Daysee",
    "effectiveTime": "20250512",
    "indications_original": "Daysee\u2122 is indicated for use by females of reproductive potential to prevent pregnancy.",
    "contraindications_original": "Take one tablet daily by mouth at the same time every day for 91 days in the order directed on the blister pack. ( 2 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] are available in Extended-Cycle Wallets each containing a 13-week supply of tablets: 84 light blue tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and 7 mustard tablets, each containing 0.01 mg of ethinyl estradiol. The light blue tablets are round, biconvex, film-coated tablets, debossed with \"LU\" on one side and \"V21\" on the other side. The mustard tablets are round, biconvex, film-coated tablets debossed with \"LU\" on one side and \"V22\" on the other side.\n                  They are supplied as follows:\n                  Daysee [levonorgestrel and ethinyl estradiol tablets USP (0.15 mg/0.03 mg) and ethinyl estradiol tablets USP (0.01 mg)] is available in an extended cycle wallet of 91 tablets which is packed in a pouch (NDC 68180-846-11). Such two pouches are packed in a carton (NDC 68180-846-13).\n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0 C to 25\u00b0 C (68\u00b0 F to 77\u00b0 F); excursions permitted to 15\u00b0C to 30\u00b0 C (59\u00b0F to 86\u00b0 F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Daysee is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     A high risk of arterial or venous thrombotic diseases. Examples include females who are known to:\n                     Smoke, if over age 35 [see Boxed Warnings and Warnings and Precautions (5.1)].\n                     Have current or history of deep vein thrombosis or pulmonary embolism [see Warnings and Precautions (5.1)].\n                     Have cerebrovascular disease [see Warnings and Precautions (5.1)]\n                     Have coronary artery disease [see Warnings and Precautions (5.1)].\n                     Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)].\n                     Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)].\n                     Have uncontrolled hypertension or hypertension with vascular disease [see Warnings and Precautions (5.3)].\n                     Have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or with vascular disease or other end-organ damage, or diabetes mellitus of >20 years duration [see Warnings and Precautions (5.7)].\n                     Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches [see Warnings and Precautions (5.8)].\n                     Current diagnosis of, or history of, breast cancer, which may be hormone sensitive [see Warnings and Precautions (5.11)].\n                     Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis [see WARNINGS AND Warnings and Precautions (5.2) and Use in Specific Populations (8.6)].\n                     Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.9)]\n                     Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "Daysee"
        }
    ]
}